Abstract
Cutaneous pseudolymphoma (C-PSL) is characterized by heterogenous lymphoproliferative processes contributing to skin lesions which histologically and clinically mimic malignant cutaneous lymphomas. It is of most importance to diagnose such case precisely and discriminate them from malignant lymphomas since treatment protocols are distinctive. Standard medical approaches for C-PSL includes elimination of causative factors, topical, intralesional and systemic steroids, hydroxychloroquine, and photodynamic therapy. Rituximab as an anti CD20 monoclonal antibody was used in this study to treat a patient with 8 years clinical features of pseudolymphoma with no positive response to routine medications. Follow up of almost more than 18 months revealed a successful treatment without noticeable side effects or disease recurrence.
Highlights
Being described for the first time by Kaposi (1891), cutaneous pseudolymphoma (C-PSL) or cutaneous lymphoid hyperplasia (CLH) is a condition characterized by localized or disseminated benign reactive polyclonal either T-cell or B-cell proliferation in reaction to several known or unknown stimuli. It refers to skin lesions and heterogeneous lymphoproliferative processes that histologically and/or clinically resemble malignant cutaneous lymphomas most of the time
In a study by Dragonetti et al in 2004 a patient with cutaneous pseudolymphomas was successfully treated with hydroxychloroquine sulfate [400 mg/die for three months] as the definite cause was not found
C-25 the major treatment scenario in this case. Strong evidences of such interactions in rituximab mechanisms of action have culminated with the development of novel strategies for NK cell mediated cell lysis like development of generation anti-CD20 antibodies with robust affinity for CD16 [14]. It has been suggested by indirect evidences that regression of B cell lymphoma independent of strong immune participation can be induced by anti-CD20 therapy
Summary
Being described for the first time by Kaposi (1891), cutaneous pseudolymphoma (C-PSL) or cutaneous lymphoid hyperplasia (CLH) is a condition characterized by localized or disseminated benign reactive polyclonal either T-cell or B-cell proliferation in reaction to several known or unknown stimuli It refers to skin lesions and heterogeneous lymphoproliferative processes that histologically and/or clinically resemble malignant cutaneous lymphomas most of the time. We report a 38 years old female patient diagnosed as pseudolymphoma case for 8 years, who represented papules, plaques, and dense erythematous nodules in whole face, chick, and forehead in clinical skin examination. She had diffused lesions on her both forearms. There was only compliance over occasional itchy state of healed lesions
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
